

# Drug Utilization Study (DUS) and post authorization safety study (PASS) on the fixed combination Tramadol-Dexketoprofen (DKP-TRAM)

**First published:** 26/05/2021

**Last updated:** 22/02/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS24858

---

### Study ID

46777

---

### DARWIN EU® study

No

---

### Study countries

 Italy

 Spain

---

## Study description

To evaluate pattern of prescription of DKP-TRAM and assess the risk of adverse events in DKP-TRAM vs. Tramadol monotherapy users with a special focus on patients 75 year-old and over

---

## Study status

Finalised

## Research institutions and networks

### Institutions

Health Search, Italian College of General Practicioners

 Italy

**First published:** 02/03/2010

**Last updated:** 20/08/2024

**Institution**

Educational Institution

Other

Multiple centres: 2 centres are involved in the study

## Contact details

### Study institution contact

Fabrizzi Paolo pfabrizzi@menarini.it

Study contact

[pfabrizzi@menarini.it](mailto:pfabrizzi@menarini.it)

**Primary lead investigator**

Lapi Francesco

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Actual: 06/06/2018

---

**Study start date**

Planned: 01/01/2017

Actual: 01/01/2017

---

**Data analysis start date**

Planned: 01/01/2017

Actual: 01/01/2017

---

**Date of interim report, if expected**

Planned: 31/01/2021

Actual: 31/01/2021

---

**Date of final study report**

Planned: 10/08/2021

Actual: 10/08/2021

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Menarini International Operations Luxembourg

## Study protocol

[protocollo finale versione 1.pdf](#) (5.81 MB)

[protocollo finale versione 3.pdf](#) (648.67 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 1 (imposed as condition of marketing authorisation)

## Methodological aspects

### Study type

### Study type list

#### **Study topic:**

Human medicinal product

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Drug utilisation

Safety study (incl. comparative)

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

To evaluate pattern of drug use (i.e. indication, dosage and duration) of DKP-TRAM

## Study Design

**Non-interventional study design**

Cohort

Other

---

**Non-interventional study design, other**

Post authorization safety study (PASS)

## Study drug and medical condition

## **Anatomical Therapeutic Chemical (ATC) code**

(N02AJ14) tramadol and dexketoprofen

tramadol and dexketoprofen

(N02AJ13) tramadol and paracetamol

tramadol and paracetamol

(N02AX02) tramadol

tramadol

---

## **Medical condition to be studied**

Pain

## Population studied

### **Short description of the study population**

All patients aged 18 years or older being registered in the databases between January 1, 2017 and December 31, 2018.

#### Inclusion criteria

Primary objectives (drug utilisation): all patients aged 18 years or older with at least 1-year medical history in the database and prescribed with DKP-TRAM coded via the Anatomical Therapeutic Chemical (ATC) classification system (ATC: N02AJ14) will be identified. For each patient, the date of the first prescription of DKP-TRAM being registered in the study period will be the index date.

Secondary objectives (comparative safety): all patients aged 18 years or older and newly prescribed with DKP-TRAM (ATC: N02AJ14) or tramadol (ATC: N02AX02) or tramadol-paracetamol (ATC: N02AJ13) will be identified. For each patient, the date of the first DKP-TRAM or tramadol (including tramadol-

paracetamol)prescription in the study period will be the index date.

#### Exclusion criteria

Primary objectives (drug utilisation): Patients 1) with missing data on age or gender, 2) with less than 1-year medical history in the database, 3) aged 17 years or younger.

Secondary objectives (comparative safety): Patients 1) with missing data on age or gender, 2) with less than 1-year medical history in the database, 3) aged 17 years or younger, 4) being prescribed with tramadol (or tramadol-paracetamol) in the entire period (up to 1998 and 2010 for HSD and SIDIAP, respectively) preceding the index date.

---

#### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

#### **Estimated number of subjects**

2828

## Study design details

#### **Outcomes**

Indication, duration and dosage of medications use, demographic factors, life style factors, comorbidities, co-medications and prescriber type (GP or specialist). Adverse events (e.g. nausea, vomiting, diarrhoea, vertigo, allucinations and somnolence) in incident users of DKP-TRAM vs. incident user

of Tramadol as monotherapy (including fixed combination tramadol-paracetamol), with a special focus on patients 75 year-old and over.

---

### **Data analysis plan**

Primary objectives: Crude age- and sex- standardised incidence rate (IR) of DKP-TRAM use will be computed, along with descriptive analysis concerning indication, duration and dosage. Continuous variables will be describe as mean with standard deviation or median with interquartile range. Categorical variables will be described as N and percentages. Secondary objectives: The risk of AEs in users of DKP-TRAM will be compared with the risk of AEs in users of tramadol as monotherapy by estimating HR with related 95% confidence intervals (CI) through Cox regression model. Tramadol monotherapy users will be the reference category. All these analysis will be updated with information on data entering the databases in 2018.

## Documents

### **Study results**

[FINAL\\_PASS\\_Menarini\\_DKP\\_TRAM\\_final\\_report\\_V04\\_\\_Clean 14.01.22.pdf](#) (1.39 MB)

---

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

**Data source(s)**

Health Search/IQVIA Health Longitudinal Patient Database  
The Information System for Research in Primary Care (SIDIAP)

---

**Data sources (types)**

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No